Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Status:
Terminated
Trial end date:
2018-09-14
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the continued safety of topical use of SD-101 cream
(6%) in participants with Epidermolysis Bullosa (EB).
Funding Source: FDA Office of Orphan Products Development
Phase:
Phase 2
Details
Lead Sponsor:
Scioderm, Inc.
Collaborators:
Amicus Therapeutics Food and Drug Administration (FDA)